



Press release

Stockholm, 8 October 2026

Invitation: Sobi's Q3 2026 report

Sobi plans to publish its report for the third quarter of 2026 on 27 October 2026 at 08:00 CET.

Investors, analysts, and the media are invited to a conference call on the same day at 15:00 CET, 14:00 GMT, and 10:00 EDT. The call will include a presentation of the results and a Q&A session.

The presentation can be followed live [here](#) or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:

HD Web Phone™: [click here](#)

Sweden: +46 8 5051 0031

United Kingdom: +44 203 059 58 63

United States: +1 631 570 56 13

For other countries, please find the details [here](#).

Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and [LinkedIn](#).

Contacts

For details on how to contact the Sobi Investor Relations Team, please click [here](#). For Sobi Media contacts, click [here](#).

Gerard Tobin
Head of Investor Relations